WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.
